Eur J Anaesthesiol:​呼气末正压/肺复张动作与呼气末零压对儿童肺不张影响:一项随机临床试验

2021-09-23 “罂粟花”公众号 “罂粟花”公众号

背景

背景

肺不张是常见的术后并发症。围手术期肺保护可以减少肺不张;然而,这种情况是否会持续到术后还不清楚。

目的

评估肺保护性通气在何种程度上减少接受非腹部手术的儿童围手术期肺不张。

试验设计

随机、对照、双盲研究。

范围设置

2019年7月25日至2020年1月18日的单中心三级医院。

受试患者

共纳入了60名年龄在1-6岁、美国麻醉医师协会分级I~II级的患儿,计划在机械通气的全麻(≤2h)下进行非腹部手术。

干扰因素

患者被随机分为肺保护组和零呼气末压力组(对照组)。肺保护需要每30min进行5cmH2O呼气末正压和肺复张动作。两组均采用容量控制通气,潮气量6ml kg-1体重。分别于麻醉诱导前、诱导后即刻、手术拔管即刻、拔管后15min、3h、12h、24h进行肺部超声检查。

主要观察指标

比较各组在各时间段肺部超声评分的差异。得分越高,说明肺部充气状况越差。

结果

与对照组患者相比,肺保护组患者术后即刻肺部超声评分中位数[IQR]更低(4[4~5] vs. 8[4~6],组间差异的95%可信区间为-4~-4,Z=-6.324)和拔管后也表现相同情况(3[3~4] vs. 4[4~4],95%CI -1~0,Z=-3.161)。从拔管后15分钟开始,这种情况不再持续。两组拔管后3h肺通气均恢复正常。

结论

肺保护性通气减少的肺不张从拔管后15min开始不再持续。还需要进一步的研究来确定它在其他类型的手术中是否产生更好的效果。

原始出处:

Change Zhu, Saiji Zhang, Junli Dong, et al. Effects of positive end-expiratory pressure/recruitment manoeuvres compared with zero end-expiratory pressure on atelectasis in children: A randomised clinical trial [J]Eur J Anaesthesiol 2021; 38:908–915.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051695, encodeId=cc70205169507, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 27 21:17:55 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661406, encodeId=0e391661406dc, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Wed Jul 27 06:17:55 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704027, encodeId=b0d11e04027b2, content=<a href='/topic/show?id=9be48201e95' target=_blank style='color:#2F92EE;'>#肺不张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82017, encryptionId=9be48201e95, topicName=肺不张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbb30623963, createdName=mnda, createdTime=Tue Apr 26 01:17:55 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633612, encodeId=31c31633612a8, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 20 19:17:55 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506816, encodeId=701b1506816f1, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588478, encodeId=305715884e84a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051695, encodeId=cc70205169507, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 27 21:17:55 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661406, encodeId=0e391661406dc, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Wed Jul 27 06:17:55 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704027, encodeId=b0d11e04027b2, content=<a href='/topic/show?id=9be48201e95' target=_blank style='color:#2F92EE;'>#肺不张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82017, encryptionId=9be48201e95, topicName=肺不张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbb30623963, createdName=mnda, createdTime=Tue Apr 26 01:17:55 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633612, encodeId=31c31633612a8, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 20 19:17:55 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506816, encodeId=701b1506816f1, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588478, encodeId=305715884e84a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051695, encodeId=cc70205169507, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 27 21:17:55 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661406, encodeId=0e391661406dc, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Wed Jul 27 06:17:55 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704027, encodeId=b0d11e04027b2, content=<a href='/topic/show?id=9be48201e95' target=_blank style='color:#2F92EE;'>#肺不张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82017, encryptionId=9be48201e95, topicName=肺不张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbb30623963, createdName=mnda, createdTime=Tue Apr 26 01:17:55 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633612, encodeId=31c31633612a8, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 20 19:17:55 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506816, encodeId=701b1506816f1, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588478, encodeId=305715884e84a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2022-04-26 mnda
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051695, encodeId=cc70205169507, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 27 21:17:55 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661406, encodeId=0e391661406dc, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Wed Jul 27 06:17:55 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704027, encodeId=b0d11e04027b2, content=<a href='/topic/show?id=9be48201e95' target=_blank style='color:#2F92EE;'>#肺不张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82017, encryptionId=9be48201e95, topicName=肺不张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbb30623963, createdName=mnda, createdTime=Tue Apr 26 01:17:55 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633612, encodeId=31c31633612a8, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 20 19:17:55 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506816, encodeId=701b1506816f1, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588478, encodeId=305715884e84a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-11-20 AspirantSuo
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051695, encodeId=cc70205169507, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 27 21:17:55 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661406, encodeId=0e391661406dc, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Wed Jul 27 06:17:55 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704027, encodeId=b0d11e04027b2, content=<a href='/topic/show?id=9be48201e95' target=_blank style='color:#2F92EE;'>#肺不张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82017, encryptionId=9be48201e95, topicName=肺不张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbb30623963, createdName=mnda, createdTime=Tue Apr 26 01:17:55 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633612, encodeId=31c31633612a8, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 20 19:17:55 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506816, encodeId=701b1506816f1, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588478, encodeId=305715884e84a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2051695, encodeId=cc70205169507, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Thu Jan 27 21:17:55 CST 2022, time=2022-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661406, encodeId=0e391661406dc, content=<a href='/topic/show?id=5f119844112' target=_blank style='color:#2F92EE;'>#随机临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98441, encryptionId=5f119844112, topicName=随机临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbb125274547, createdName=ms117281293605716, createdTime=Wed Jul 27 06:17:55 CST 2022, time=2022-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704027, encodeId=b0d11e04027b2, content=<a href='/topic/show?id=9be48201e95' target=_blank style='color:#2F92EE;'>#肺不张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82017, encryptionId=9be48201e95, topicName=肺不张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbb30623963, createdName=mnda, createdTime=Tue Apr 26 01:17:55 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633612, encodeId=31c31633612a8, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Sat Nov 20 19:17:55 CST 2021, time=2021-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506816, encodeId=701b1506816f1, content=<a href='/topic/show?id=4a6c82100de' target=_blank style='color:#2F92EE;'>#肺复张#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82100, encryptionId=4a6c82100de, topicName=肺复张)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49409820194, createdName=apoenzyme, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588478, encodeId=305715884e84a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sat Sep 25 00:17:55 CST 2021, time=2021-09-25, status=1, ipAttribution=)]
    2021-09-25 skhzy